50.47 -0.05 (-0.10%)
After hours: 4:11PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||50.18 - 50.71|
|52-week range||33.10 - 58.37|
|PE ratio (TTM)||19.87|
|Forward dividend & yield||0.95 (1.88%)|
|1y target est||60.40|
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.
Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017, a 252% YoY (year-over-year) rise on a reported basis and a 255% YoY rise in local currencies. The uptake of Xultophy, a combination of Tresiba and Victoza, was mainly driven by increasing demand in European and North American markets. Xultophy secured approval from the FDA on November 21, 2016, as a once-daily injectable adjunct therapy for type 2 diabetes patients who don’t respond adequately to a daily intake of 50 units of basal insulin or up to 1.8 mg of Victoza (liraglutide).
Novo Nordisk (NVO) has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among GPs (general practitioner) and PCPs (primary care physician). Patients suffering from type 1 diabetes are generally treated by endocrinologists, who focus on factors such as low intra-patient glycemic variability, a flat and stable drug profile, fewer hypoglycemia events, patient convenience, and confidence in the product while prescribing drugs. Because GPs and PCPs don’t focus on glycemic variability and hypoglycemia events, Novo Nordisk’s efforts to raise awareness are expected to drive the adoption of Tresiba in the type 2 diabetes patient population.
Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18. In 4Q17, the company also submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for updating Tresiba’s label to reflect hypoglycemia data from the DEVOTE trial. Novo Nordisk is anticipating a readout of the results from its trial comparing Tresiba to insulin glargine U300 in 4Q18.
In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status. The drug has witnessed rapid uptake in markets in which it has par access compared to competing products, such as insulin glargine U100. In the United States, Novo Nordisk managed to attain a 34% share of the total basal insulin market by volume as of January 2018.
Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies. The company considers affordability to be the key commercial aspect of its human insulin portfolio, which mainly caters to diabetes patients with lower purchasing power. Novo Nordisk believes that high familiarity owing to long-term presence in the market is a major competitive advantage for its modern insulin portfolio.
According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes. Of these, 11.2 million patients are estimated to be treated with the company’s human insulin products, 12.5 million with its modern insulin products, 0.9 million with its new-generation insulin products, and the remaining 1.4 million with its glucagon-like peptide 1 (or GLP-1) products.
In the diabetes care segment, the company is currently focused on developing insulin and glucagon-like peptide 1 (or GLP-1) products, which demonstrate distinct clinical advantages in terms of factors such as the absence of hypoglycemia, reduced comorbidity risk related to cardiovascular events, and weight loss. Novo Nordisk is also evaluating new treatment options with improved delivery mechanisms, such as oral delivery. The above diagram shows the evolution of Novo Nordisk’s insulin and GLP-1 franchises since 1923 and 1986, respectively.
On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1, which evaluated the efficacy of oral semaglutide as a treatment option for type 2 diabetes patients in three different daily dosages: 3 mg, 7 mg, and 14 mg. The investigational therapy demonstrated a statistically significant improvement in blood glucose levels compared to the placebo irrespective of the treatment adherence rates of the patients. In cases where patients adhered to the treatment regimen properly, all oral semaglutide dosages demonstrated a robust drop in both the blood glucose levels and body weights of the patients.
The FDA’s approval of Novo Nordisk’s (NVO) Ozempic (semaglutide) was based on favorable results from its Phase 3a study, SUSTAIN, which highlighted the superiority of the drug as a monotherapy or in combination with other agents in reducing blood glucose levels and body weight in type 2 diabetes patients. While there is a risk of retinopathy associated with Ozempic, the FDA’s guidance for this side effect is similar to what’s included on insulin labels. Ozempic has been launched in the United States as a prefilled device, and it’s available in 0.5 mg and 1 mg doses.
Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets." (Source: Bloomberg)
Mar.02 -- Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets."